PTC completes acquisition of Sangamo's Fabry gene therapy.
PTC Therapeutics acquired the BLA-stage ST-920 gene therapy from Sangamo, targeting a Q4 2026 FDA submission for accelerated approval. The deal expands PTC's portfolio into gene therapy for Fabry disease.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed